Dr. van den Bent on INTELLANCE 2 Trial for Recurrent Glioblastoma
Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the INTELLANCE 2 trial for recurrent glioblastoma.
Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the INTELLANCE 2 trial for recurrent glioblastoma. He presented updated data at the 2018 ASCO Annual Meeting.
About 50% of glioblastoma cases are characterized by EGFR mutations, but recent trials with EGFR inhibitors have not worked. Since the introduction of radiotherapy combined with temozolomide (Temodal) as the standard of care, physicians have not made any progress, says van den Bent. INTELLANCE 2, a randomized phase II trial, tests the antibody-drug conjugate depatux-m alone, depatuxizumab mafodotin (depatux-m) with temozolomide, and a control arm of either temozolomide or lomustine (Gleostine) alone.
After a 1-year follow-up, the combination of depatux-m and temozolomide resulted in a median 1-year overall survival rate of 40%, compared with 28% in the control arm. Patients on the combination arm were treated with depatux-m 1 mg/kg every 2 weeks and temozolomide 150 mg-200 mg/kg2 days 1 to 5 every 4 weeks.
